Clinical Research

Clinical research studies which are currently enrolling interventional cardiology patients at the University of Minnesota Medical Center:

Contrast nephropathy in ad hoc vs. staged percutaneous coronary interventions with kidney disease

Patients with chronic kidney disease (CKD) have a higher risk for cardiovascular disease.  Angiography in those with CKD who are not on dialysis is a challenge due to the concern of contrast nephropathy.  Percutaneous coronary intervention (PCI) is often staged in this population due to the concern over larger volumes of contrast worsening kidney function.  Recent data reveal that those who received the iso-osmolar contrast agent iodixanol had a significantly-lower incidence of contrast nephropathy compared to the low-osmolar agent iohexol.  More importantly, the relationship volume of iodixanol contrast to worsening kidney function is not apparent, contrary to data with iohexol contrast.

OBJECTIVES:

1.)  In a randomized fashion, compare incidence of contast nephropathy in ad hoc vs. staged PCI in those with moderate-to-severe CKD (GFR < 60 mL / min).

2.)  To compare cost of procedures and complications relating to procedures in ad hoc vs. staged PCI.

3.)  To compare complications from cardiac catheterization in ad hoc vs. staged PCI groups.

FUNDING:

American Heart Association Scientist Development Grant

PRIMARY INVESTIGATOR:

Ganesh Raveendran, M.D.

For more information, please call (612) 625-4465.

Triton TIMI-38:  a comparison of CS-747 (prasugrel) and clopidogrel in acute-coronary-syndrome subjects who are to undergo percutaneous coronary intervention

For more information, go to

http://www.lillytrials.com/initiated/studies/initiated_8695.html